bendamustine hydrochloride has been researched along with Hematologic Malignancies in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bedini, A; Bettelli, F; Dolci, G; Franceschini, E; Fregni-Serpini, G; Grottola, A; Guaraldi, G; Luppi, M; Meschiari, M; Mussini, C; Pecorari, M; Pellegrino, M; Perno, CF; Sarti, M; Todisco, V | 1 |
| Abedi, M; Davis, J; Hoeg, RT; Jonas, BA; Rosenberg, A; Tuscano, J | 1 |
| Benedetti, L; Bergamaschi, M; Briani, C; Demichelis, C; Ferrari, S; Garnero, M; Massa, F; Pesce, G; Schenone, A; Zuppa, A | 1 |
| Bétrian, S; Demur, C; Guenounou, S; Huguet, F; Huynh, A; Luquet, I; Recher, C; Ysebaert, L | 1 |
| Chiba, A; Kurokawa, M; Nakamura, F; Nakazaki, K | 1 |
| Katsanis, E; Koza, S; Sapp, LN; Stea, B; Varner, N; Zeng, Y | 1 |
| Catalano, L; Cerchione, C; De Renzo, A; Della Pepa, R; Di Perna, M; Nappi, D; Pane, F; Picardi, M; Pugliese, N | 1 |
| Al-Kali, A; Chintakuntlawar, A; Kidd, M; Thompson, CA; Wilson, W | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Bond, M; Chovan, JP; Darwish, M; Hellriegel, E; Robertson, P | 1 |
| Brugger, W; Cheson, BD; Damaj, G; Dreyling, M; Kahl, B; Kimby, E; Ogura, M; Weidmann, E; Wendtner, CM; Zinzani, PL | 1 |
| Gafter-Gvili, A; Polliack, A | 1 |
| Cheson, BD | 2 |
| Blumel, S; Dang, NH; Goodrich, A; Martin, C | 1 |
| Bischofs, E; Eichbaum, M; Nehls, K; Schneeweiss, A; Sohn, C | 1 |
| Hartley, JA; Leoni, LM | 1 |
| Leoni, LM | 1 |
| Cheson, BD; Leoni, L | 1 |
| Cheson, BD; Diehl, V | 1 |
| Schrijvers, D; Vermorken, JB | 1 |
8 review(s) available for bendamustine hydrochloride and Hematologic Malignancies
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.
Topics: Area Under Curve; Bendamustine Hydrochloride; Cytochrome P-450 CYP1A2; Drug Interactions; Hematologic Neoplasms; Humans; Nitrogen Mustard Compounds | 2015 |
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Consensus Development Conferences as Topic; Disease Management; Disease Progression; Drug Resistance; Hematologic Diseases; Hematologic Neoplasms; Humans; Recurrence; Retreatment | 2016 |
Bendamustine associated immune suppression and infections during therapy of hematological malignancies.
Topics: Agammaglobulinemia; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Hematologic Neoplasms; Humans; Immune System; Immunosuppressive Agents; Infections; Lymphopenia | 2016 |
Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; DNA; DNA Damage; Hematologic Neoplasms; Humans; Nitrogen Mustard Compounds | 2011 |
Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century.
Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Humans; Nitrogen Mustard Compounds | 2011 |
Bendamustine: mechanism of action and clinical data.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Nitrogen Mustard Compounds | 2011 |
Phase I studies with bendamustine: an update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Europe; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphopenia; Multiple Myeloma; Nitrogen Mustard Compounds; Research Design | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
2 trial(s) available for bendamustine hydrochloride and Hematologic Malignancies
| Article | Year |
|---|---|
A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Everolimus; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Young Adult | 2020 |
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.
Topics: Adolescent; Adult; Allografts; Bendamustine Hydrochloride; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Young Adult | 2018 |
11 other study(ies) available for bendamustine hydrochloride and Hematologic Malignancies
| Article | Year |
|---|---|
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; COVID-19; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Rituximab; SARS-CoV-2 | 2023 |
Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy.
Topics: Bendamustine Hydrochloride; Hematologic Neoplasms; Humans; Myelin-Associated Glycoprotein; Neoplasm Recurrence, Local; Polyneuropathies; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Rituximab | 2020 |
Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Blast Crisis; Dendritic Cells; Hematologic Neoplasms; Humans; Male; Middle Aged; Recurrence | 2017 |
Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine.
Topics: Aged; Aged, 80 and over; Antigens, Viral; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cytomegalovirus; Cytomegalovirus Infections; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Neoplasms; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Virus Activation | 2018 |
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.
Topics: Aged; Bendamustine Hydrochloride; Febrile Neutropenia; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Polyethylene Glycols | 2019 |
Toxoplasmosis in patients with hematologic malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diagnosis, Differential; Female; Hematologic Neoplasms; Humans; Rituximab; Toxoplasma; Toxoplasmosis, Cerebral | 2015 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Bendamustine: a new therapeutic option for hematologic malignancies.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Humans; Nitrogen Mustard Compounds | 2008 |
Bendamustine: a novel cytotoxic agent for hematologic malignancies.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Nitrogen Mustard Compounds | 2008 |
Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine.
Topics: Alkylating Agents; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Neoplasms; Nitrogen Mustard Compounds | 2009 |
Bendamustine in the treatment of hematologic malignancies. Introduction.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds | 2002 |